NCT05350683 (RIPC-EVAR) is a Phase 2 clinical trial of Remote ischemic preconditioning in Aortic Aneurysm, sponsored by Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery.

What drugs are being tested in NCT05350683?

Interventions in NCT05350683: Remote ischemic preconditioning.

What condition does NCT05350683 study?

NCT05350683 studies Aortic Aneurysm, Ischemic Preconditioning.

Is NCT05350683 still recruiting?

NCT05350683 is currently completed. Last updated 28 April 2022.

Last reviewed 2022-04-28 · How we verify

NCT05350683: RIPC-EVAR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Remote Ischemic Preconditioning on the Incidence of Contrast Induced Nephropathy in Patients Undergoing EVAR

Completed Phase 2 Last updated 28 April 2022

What this trial tests

Phase 2 trial testing Remote ischemic preconditioning in Aortic Aneurysm in 120 participants. Completed in 20 May 2020.

Timeline

1 January 2017

Primary endpoint
17 September 2019

20 May 2020

Quick facts

Lead sponsor	Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	120
Start date	1 January 2017
Primary completion	17 September 2019
Estimated completion	20 May 2020
Sites	1 location across Spain

Drugs / interventions tested

Remote ischemic preconditioning

Conditions studied

Aortic Aneurysm — all drugs for Aortic Aneurysm →
Ischemic Preconditioning — all drugs for Ischemic Preconditioning →

Sponsor

Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery

Who can join

Eligibility, any sex, with Aortic Aneurysm or Ischemic Preconditioning. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Introduction: Contrast induced nephropathy (CIN) is a major inconvenience in the use of iodinated contrast media (ICM) and it is associated with a significant increase in morbimortality and cost of hospitalization. Remote ischemic preconditioning (RIPC) is a non-invasive and cost-effective tissular protection technique that has proven beneficial in decreasing renal insult in patients receiving intravascular contrast. Aim: The primary outcome of this study is to evaluate the impact of RIPC on the incidence of CIN in patients undergoing endovascular aneurysm repair.Material and Methods: Patients suffering from aortic aneurysm were recruited prior to the administration of iodinated contrast media. Randomization was used to assign patients into the control/RIPC groups. Biochemical parameters determined renal function before and after surgery in immediate (24-72 hours) and at 30 days' follow-up.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Remote ischemic preconditioning

Trials testing the same drug.

NCT06170944 — Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke · NA · recruiting
NCT05990907 — Influence of RIC on the Orthostatic Competence of the Microcirculation · NA · unknown
NCT05733208 — The Effect of Remote Ischemic Preconditioning on Myocardial Injury After Noncardiac Surgery · NA · active not recruiting
NCT05567341 — Remote Ischemic Preconditioning in Vestibular Schwannoma Surgery · NA · unknown
NCT05364333 — Remote Ischemic Preconditioning and Acute Kidney Injury in HTX · NA · completed

Other recruiting trials for Aortic Aneurysm

Currently open trials in the same condition.

NCT07438327 — AI-CARE: Artificial Intelligence for Cardiovascular Analysis and Risk Evaluation · recruiting
NCT06998498 — Prehabilitation for Aortic Aneurysm Surgery: Proof-of-concept Trial · NA · recruiting
NCT06549348 — Radiation Free Study · NA · recruiting
NCT06834607 — Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Complex Aortic Aneurysms · NA · recruiting
NCT06762561 — Prophylactic Mesh Reinforcement After Open Aortic Aneurysm Repair · recruiting

Other Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery trials

Trials by the same sponsor.

NCT06012123 — BS-CERAB TECHNIQUE · completed
NCT05309707 — ENDOBARC-S Study: "Endovascular Branched Stent-grafts for Aortic ARCh Pathologies in Spain" · recruiting
NCT04333693 — Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study · unknown
NCT05617053 — DAART vs PTA/SUPERA STENTING FOR POPLITEAL ARTERY LESIONS · completed
NCT04756115 — Impact of Nutritional and Inflammatory Status in Patients With Critical Limb-threatening Ischemia · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05350683 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery
Last refreshed: 28 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05350683.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing